ClinicalTrials.gg
Drug

Acalabrutinib clinical trials

Also written ACP-196 and Calquence.

Includes 1 study of Acalabrutinib maleate anhydrous.

studies test it
123
open now
27
in phase 3
17
first study started
2014

How each study uses acalabrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the acalabrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 Oct 2017 · CALQUENCE · NDA 210259 (FDA, Drugs@FDA)
European Union
5 Nov 2020 · Calquence · EMEA/H/C/005299 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Acalabrutinib
105
Bruton Tyrosine Kinase Inhibitor ACP-196
25
Acalabrutinib (ACP-196)
2
1420477-60-6
2
ACP-196 (acalabrutinib)
2

Brand

Calquence
41

Development codes

ACP-196
52

In one entry with another drug

Given together, or one or the other

R-CHOP + acalabrutinib
2
ACP-196 in combination with pembrolizumab
2

Studies by the year they started

122 studies that test it; most in 2021 (22); 1 more planned to start later

Studies that test acalabrutinib, by start year
YearStudies
20147
201512
20167
20176
20184
201912
202021
202122
20226
20239
20246
20256
20264

Who runs them

Industry 52 · Other 71

Acerta Pharma BV (33) · AstraZeneca (16) · M.D. Anderson Cancer Center (9) · City of Hope Medical Center (5) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Washington University School of Medicine (2) · University of Washington (2)

Often tested with

Tested in the same studies.

Obinutuzumab (16) · Venetoclax (15) · Rituximab (14) · Tafasitamab (5) · Lenalidomide (4) · Bendamustine (3) · Ibrutinib (3) · Durvalumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Acalabrutinib is the comparator. A study of two new drugs counts under both.

  • 1Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Nov 2027
  • 1ARQ531 · Merck Sharp & Dohme LLC · next primary completion Sep 2032
  • 1Sonrotoclax · BeOne Medicines · next primary completion Feb 2031
  • 1Zanubrutinib · BeOne Medicines · next primary completion Feb 2031
  • 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 26, 5 in phase 3

Studies that test acalabrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses acalabrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 123

See all 123 studies that test acalabrutinib →

Given beside what is tested · 22 — acalabrutinib is usual care or a partner of the new treatment

Showing 20 of 22.

As the comparator · 4 — what is tested is compared with acalabrutinib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call acalabrutinib · ClinicalTrials.gg INT000401

  • MeSH (NLM) C000604908acalabrutinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) I42748ELQWACALABRUTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1986808Confirmed FDA, Wikidata
  • Wikidata Q23668732acalabrutinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C113442AcalabrutinibOne source FDA
  • DrugBank DB11703One source Wikidata

Also registered as acalabrutinib maleate monohydrate (UNII 9GP2BPG9NS).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.